Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) Consolidated Net Income (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Consolidated Net Income for 16 consecutive years, with -$6.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Consolidated Net Income fell 162.81% to -$6.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $17.6 million, a 67.69% decrease, with the full-year FY2024 number at $42.1 million, down 34.06% from a year prior.
  • Consolidated Net Income was -$6.7 million for Q3 2025 at Usana Health Sciences, down from $10.4 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $40.4 million in Q4 2021 to a low of -$6.7 million in Q3 2025.
  • A 5-year average of $17.3 million and a median of $16.5 million in 2024 define the central range for Consolidated Net Income.
  • Peak YoY movement for Consolidated Net Income: soared 36.66% in 2021, then plummeted 162.81% in 2025.
  • Usana Health Sciences' Consolidated Net Income stood at $40.4 million in 2021, then tumbled by 68.29% to $12.8 million in 2022, then soared by 31.04% to $16.8 million in 2023, then plummeted by 73.26% to $4.5 million in 2024, then tumbled by 248.57% to -$6.7 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Consolidated Net Income are -$6.7 million (Q3 2025), $10.4 million (Q2 2025), and $9.3 million (Q1 2025).